Healthtech - So Hot Right Now... Demystifying Funding in Healthtech
Event description
💰Demystifying Funding in Healthtech 💊
With >$30B invested globally in healthtech in just 3 quarters, it’s pretty clear healthtech is the place to be.
There’s a flood of interest from founders, operators, clinicians and investors - but there's a lot of hype and hysteria, and it's hard to cut through the fluff and find actual quality insights and advice.
So instead, come hear first hand from this panel of experienced experts to dispel myths, discuss the realities of raising capital, and dish out their opinions on top trends in healthcare and creating great healthtech companies.
We’ll cover the ins and outs of healthtech investing, including:
- What these investors look for in healthtech companies and founders
- Dispel classic myths and misconceptions about raising
- Top trends and opportunities in health innovation right now
- The right to play and the winning combination - for both future founders and investors
This is for any founders (or future founders) interested in learning about how these investors think, investors and operators keen to get a mix of insights into healthtech investment, or general healthtech enthusiasts
Panellists
1. Alister Coleman (Folklore Ventures)
Alister is the founder and Managing Partner of Folklore, a first cheque venture capital firm backing startups built by Australian and New Zealand founders with global ambition, including HealthMatch, Arli and Swoop Aero. Prior to starting Folklore in 2013, he co-founded ShippingEasy (acquired in 2016), and has more than 15 years’ experience as a VC, founder and adviser to technology companies
2. Ben Armstrong (Archangel Ventures)
Ben is an active angel and co-founder of Archangel Ventures an early-stage investment firm investing in Australian and New Zealand founders. He's been investing in healthcare for nearly a decade. His current investments in health include Eugene, Lasertrade, Oscer.ai, Ovira and Vively. Prior to investing Ben helped develop Telstra's health strategy and helped with the due diligence, investment and acquisition of several digital health-related assets and sat on boards including as the first non-medical person on the board of the Australian Medical Association's publishing company.
3. Dr Amandeep Hansra (Medical Angels)
Amandeep is a practising GP in the Eastern Suburbs of Sydney but has been in the health tech sector for over a decade. She was the inaugural CMO and CEO of Telstra's telehealth business and then went on to set up a telehealth business in the Philippines which is now owned by the Swiss company Medgate. She is the founder of Creative Careers in Medicine, a community of over 13000 doctors who think creatively about healthcare and their careers. She is also a co-founder of Australian Medical Angels, an angel syndicate group of doctors who invest in health tech and medical devices. She has worked with many digital health companies including Teladoc, Healthengine, Swiftdoc, Doctor Care Anywhere, CancerAid, Medical Director, Honeysuckle Health and chairs the board of Australia's largest telehealth platform company, Coviu. She also sits on the board of AMA NSW, Molemap Au/ NZ, NPS MedicineWise and ACHS International. Amandeep is also a partner at Healthcare Ventures, a new Digital Health Fund for Australia.
4. Dr Melissa Byrne (Brandon Capital Partners)
Dr Melissa Byrne has spent more than 15 years in the life sciences industry, with her expertise and experience spanning cardiovascular physiology, medical research, research translation, and commercialisation.
A cardiovascular physiologist with commercial and academic experience, Melissa is passionate about taking research from the lab to the clinic. Prior to joining Brandon Capital, Melissa managed pre-clinical research at the Baker Heart Institute in Melbourne, where she was responsible for leading studies in animal models to prepare technologies for clinical development. There, Melissa conducted preclinical research trials for sponsors developing medical devices and therapeutics. The pre-clinical developmental and safety trials, including first-in-man studies that Melissa has completed and been involved in, have been pivotal for both the commercialisation and transfer of knowledge for a number of cardiovascular devices for use in the clinical setting. As a consequence she has been a named inventor on four US patent filings, including Osprey Medical’s (ASX:OSP) DyeVert System which was spun out of the Baker Heart Institute.
Melissa was awarded a Guidant Industry Fellowship as part of an NIH Program Grant focused on improved targeting of patients for CRT therapy at Johns Hopkins Medicine, Baltimore, USA.
She has held roles for both Research & Development and Clinical Operations for a number of biotech start up companies.
Melissa has a Bachelor of Science (Honours) from The University of Melbourne, a PhD in Cardiovascular Physiology from Monash University and a Graduate Certificate, Research Commercialisation from RMIT University